{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:08:02Z","timestamp":1762250882523,"version":"3.37.3"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1124\/jpet.102.035840","type":"journal-article","created":{"date-parts":[[2003,2,27]],"date-time":"2003-02-27T18:31:38Z","timestamp":1046370698000},"page":"897-904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Drugs Targeting Alzheimer\u2019s Disease: Some Things Old and Some Things New"],"prefix":"10.1016","volume":"304","author":[{"given":"Mary L.","family":"Michaelis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.102.035840_bib1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer\u2019s disease.","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"key":"10.1124\/jpet.102.035840_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"\u03c4 protein isoforms, phosphorylation and role in neurodegenerative disorders.","volume":"33","author":"Buee","year":"2000","journal-title":"Brain Res Rev"},{"key":"10.1124\/jpet.102.035840_bib3","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0896-6273(95)90232-5","article-title":"\u03b2-amyloid fibrils induce \u03c4 phosphorylation and loss of microtubule binding.","volume":"14","author":"Busciglio","year":"1995","journal-title":"Neuron"},{"key":"10.1124\/jpet.102.035840_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1126\/science.1058783","article-title":"A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60.","volume":"293","author":"Cao","year":"2001","journal-title":"Science (Wash DC)"},{"key":"10.1124\/jpet.102.035840_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","article-title":"Treatment with a copper-zinc chelator markedly and rapidly inhibits \u03b2-amyloid accumulation in Alzheimer\u2019s disease transgenic mice.","volume":"30","author":"Cherny","year":"2001","journal-title":"Neuron"},{"key":"10.1124\/jpet.102.035840_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nsb842","article-title":"Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.","volume":"9","author":"Davies","year":"2002","journal-title":"Nat Struct Biol"},{"key":"10.1124\/jpet.102.035840_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00019052-200008000-00002","article-title":"Tau pathology: a marker of neurodegenerative disorders.","volume":"13","author":"Delacourte","year":"2000","journal-title":"Curr Opin Neurol"},{"key":"10.1124\/jpet.102.035840_bib8","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer\u2019s disease.","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science (Wash DC)"},{"key":"10.1124\/jpet.102.035840_bib9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/35096019","article-title":"A decade of Cdk5.","volume":"2","author":"Dhavan","year":"2001","journal-title":"Nature Rev"},{"key":"10.1124\/jpet.102.035840_bib10","first-page":"5249","article-title":"First human study with a benzothiazole amyloid-imaging agent in Alzheimer\u2019s disease and control subjects.","volume":"23, 51","author":"Engler","year":"2002","journal-title":"Neurobiol Aging"},{"unstructured":"Ferris SH, Schmidt F, Doody R, Moebius HJ, Stoeffler A, and Reisberg B (2001) Long-term treatment with the NMDA antagonist, memantine: results of a 24-week, open-label extension study in advanced AD. Am Coll Neuropsychopharm.","key":"10.1124\/jpet.102.035840_bib11"},{"key":"10.1124\/jpet.102.035840_bib12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.102.035840_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0798-827","article-title":"Aging renders the brain vulnerable to amyloid \u03b2-protein neurotoxicity.","volume":"4","author":"Geula","year":"1998","journal-title":"Nat Med"},{"key":"10.1124\/jpet.102.035840_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0166-2236(96)01030-2","article-title":"Amyloid, the presenilins and Alzheimer\u2019s disease.","volume":"20","author":"Hardy","year":"1997","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.102.035840_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1126\/science.290.5489.150","article-title":"Structure of the protease domain of memapsin 2 (\u03b2-secretase) complexed with inhibitor.","volume":"290","author":"Hong","year":"2000","journal-title":"Science (Wash DC)"},{"key":"10.1124\/jpet.102.035840_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A \u03b2 peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer\u2019s disease.","volume":"408","author":"Janus","year":"2000","journal-title":"Nature (Lond)"},{"key":"10.1124\/jpet.102.035840_bib17","doi-asserted-by":"crossref","first-page":"14077","DOI":"10.1074\/jbc.275.19.14077","article-title":"Alzheimer\u2019s \u03b2-amypod, human islet amylin and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line.","volume":"275","author":"Kawahara","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.102.035840_bib18","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1523\/JNEUROSCI.21-21-08354.2001","article-title":"Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein, receptor-related Protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65.","volume":"21","author":"Kinoshita","year":"2001","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.102.035840_bib19","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1101\/gad.836900","article-title":"A common enzyme connects Notch signaling and Alzheimer\u2019s disease.","volume":"14","author":"Kopan","year":"2000","journal-title":"Genes"},{"key":"10.1124\/jpet.102.035840_bib20","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1523\/JNEUROSCI.22-15-06331.2002","article-title":"Reversible memory loss in a mouse transgenic model of Alzheimer\u2019s disease.","volume":"22","author":"Kotilinek","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.102.035840_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1568026024607526","article-title":"\u03c4 protein phosphorylation as a therapeutic target in Alzheimer\u2019s disease.","volume":"2","author":"Lau","year":"2002","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/jpet.102.035840_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative tauopathies.","volume":"24","author":"Lee","year":"2001","journal-title":"Annu Rev Neurosci"},{"key":"10.1124\/jpet.102.035840_bib23","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1126\/science.1058189","article-title":"Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.","volume":"293","author":"Lewis","year":"2001","journal-title":"Science (Wash DC)"},{"key":"10.1124\/jpet.102.035840_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.2003.01526.x","article-title":"Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases \u03b2-amyloid toxicity in cortical neurons.","volume":"84","author":"Li","year":"2003","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.102.035840_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0166-4328(00)00214-X","article-title":"Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer\u2019s disease.","volume":"113","author":"Maelicke","year":"2000","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.102.035840_bib26","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome.","volume":"82","author":"Masters","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.102.035840_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0165-0173(95)00011-9","article-title":"The inflammatory response system of brain: implications for therapy of Alzheimer\u2019s and other neurodegenerative diseases.","volume":"21","author":"McGeer","year":"1995","journal-title":"Brain Res Rev"},{"key":"10.1124\/jpet.102.035840_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1385\/JMN:19:3:289","article-title":"\u03c4 neurofibrillary pathology and microtubule stability.","volume":"19","author":"Michaelis","year":"2002","journal-title":"J Mol Neurosci"},{"key":"10.1124\/jpet.102.035840_bib29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1046\/j.1471-4159.1998.70041623.x","article-title":"Protection against \u03b2-amyloid toxicity in primary neurons by paclitaxel [Taxol].","volume":"70","author":"Michaelis","year":"1998","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.102.035840_bib30","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A\u03b2 peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease.","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature (Lond)"},{"key":"10.1124\/jpet.102.035840_bib31","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/417254a","article-title":"Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.","volume":"417","author":"Pepys","year":"2002","journal-title":"Nature (Lond)"},{"key":"10.1124\/jpet.102.035840_bib32","first-page":"93","article-title":"Mild cognitive impairment: transition between aging and Alzheimer\u2019s disease.","volume":"15","author":"Petersen","year":"2000","journal-title":"Neurologia"},{"key":"10.1124\/jpet.102.035840_bib33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/35074581","article-title":"New protease inhibitors prevent gamma-secretase-mediated production of A\u03b240\/42 without affecting Notch cleavage.","volume":"3","author":"Petit","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1124\/jpet.102.035840_bib34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.2000.tb05564.x","article-title":"Apolipoprotein E and Alzheimer\u2019s disease. A role in amyloid catabolism.","volume":"924","author":"Poirier","year":"2000","journal-title":"Ann NY Acad Sci"},{"key":"10.1124\/jpet.102.035840_bib35","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1073\/pnas.092136199","article-title":"\u03c4 is essential to \u03b2-amyloid-induced neurotoxicity.","volume":"99","author":"Rapoport","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"10.1124\/jpet.102.035840_bib36","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1006\/nbdi.2001.0422","article-title":"A cholesterol-lowering drug reduces \u03b2-amyoid pathology in a transgenic mouse model of Alzheimer\u2019s disease.","volume":"8","author":"Refolo","year":"2001","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.102.035840_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0165-0173(97)00016-7","article-title":"Cholinergic activity and amyloid precursor protein metabolism.","volume":"25","author":"Roberson","year":"1997","journal-title":"Brain Res Re"},{"key":"10.1124\/jpet.102.035840_bib38","first-page":"835","article-title":"Presenilin-dependent \u03b3-secretase processing of \u03b2-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch.","volume":"2","author":"Sastre","year":"2001","journal-title":"EMBO (Eur Mol Biol Organ) J"},{"key":"10.1124\/jpet.102.035840_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/S1471-4914(02)02308-0","article-title":"Complexities in the development of cyclin-dependent kinase inhibitor drugs.","volume":"8","author":"Sausville","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1124\/jpet.102.035840_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse.","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature (Lond)"},{"key":"10.1124\/jpet.102.035840_bib41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer\u2019s disease: genes, proteins and therapy.","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.102.035840_bib42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0092-8674(00)80244-5","article-title":"Skeletal and CNS defects in presenilin-1-deficient mice.","volume":"89","author":"Shen","year":"1997","journal-title":"Cell"},{"key":"10.1124\/jpet.102.035840_bib43","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/990114","article-title":"Purification and cloning of amyloid precursor protein beta-secretase from human brain.","volume":"402","author":"Sinha","year":"1999","journal-title":"Nature (Lond)"},{"key":"10.1124\/jpet.102.035840_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0896-6273(00)00051-9","article-title":"A\u03b2-generating enzymes: recent advances in \u03b2- and \u03b3-secretase research.","volume":"27","author":"Vassar","year":"2000","journal-title":"Neuron"},{"key":"10.1124\/jpet.102.035840_bib45","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14728222.6.4.497","article-title":"Death associated protein kinase as a potential therapeutic target.","volume":"6","author":"Velentza","year":"2002","journal-title":"Expert Opin Ther Targets"},{"key":"10.1124\/jpet.102.035840_bib46","doi-asserted-by":"crossref","first-page":"25945","DOI":"10.1074\/jbc.274.36.25945","article-title":"Amyloid \u03b2-protein fibrillogenesis: structure and biological activity of protofibrillar intermediates.","volume":"274","author":"Walsh","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.102.035840_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12031-002-0016-4","article-title":"Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses.","volume":"19","author":"Watterson","year":"2002","journal-title":"J Mol Neurosci"},{"key":"10.1124\/jpet.102.035840_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic A\u03b242 independently of cyclooxygenase activity.","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature (Lond)"},{"key":"10.1124\/jpet.102.035840_bib49","first-page":"5119","article-title":"Long-term safety, tolerability and efficacy of galantamine: Results from a 36-month analysis of extension study data.","volume":"23, 51","author":"Wilcock","year":"2002","journal-title":"Neurobiol Aging"},{"key":"10.1124\/jpet.102.035840_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1385\/JMN:17:2:199","article-title":"\u03b3-Secretase inhibitors as molecular probes of presenilin function.","volume":"17","author":"Wolfe","year":"2001","journal-title":"J Mol Neurosci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524361865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524361865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.102.035840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:38:49Z","timestamp":1740008329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524361865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S0022356524361865"],"URL":"https:\/\/doi.org\/10.1124\/jpet.102.035840","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs Targeting Alzheimer\u2019s Disease: Some Things Old and Some Things New","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.102.035840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}